Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Claudio Luchini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4901-4908; OpenAlex author ID A5057229016. Sources: OpenAlex.

Their work

Papers
60 (first author 3, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
208
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 6 papers · 2021: 6 papers · 2022: 11 papers · 2023: 9 papers · 2024: 3 papers · 2025: 7 papers · 2026: 12 papers

Papers 50 of 60

  1. Pancreatic ductal adenocarcinoma and its subtypes: clinical relevance of histopathology and molecular characterization, integrating the key updates of the 2026… Co-author DOI 10.1007/s00428-026-04681-1↗
  2. Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives. Last author DOI 10.1016/j.dld.2026.03.002↗
  3. AISP position statement: Standardising biological sample collection and handling for advanced diagnostics and multi-omic analyses in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.08.021↗
  4. High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation … Last author DOI 10.1016/j.humpath.2025.106014↗
  5. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Co-author DOI 10.1038/s41467-026-69762-w↗
  6. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Last author DOI 10.1097/sla.0000000000006565↗
  7. From IPMN to invasive pancreatic cancer: new spatial insights. Last author DOI 10.1136/gutjnl-2025-337622↗
  8. KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity. Co-author DOI 10.1158/0008-5472.can-25-3126↗
  9. Metabolic plasticity underlies ferroptosis resistance driven by mutant p53 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-026-02746-y↗
  10. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  11. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  12. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  13. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  14. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  15. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Last author DOI 10.1002/path.6437↗
  16. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Co-author DOI 10.1007/s00428-025-04222-2↗
  17. Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/s41419-025-08082-1↗
  18. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  19. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  20. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. Co-author DOI 10.1002/1878-0261.13658↗
  21. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  22. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  23. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  24. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  25. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  26. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Last author DOI 10.1016/j.modpat.2023.100251↗
  27. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2022.11.015↗
  28. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  29. Co-occurring IPMN and pancreatic cancer: the same or different? An overview from histology to molecular pathology. Last author DOI 10.1136/jcp-2023-209012↗
  30. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  31. Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment. Last author DOI 10.3390/cancers15051454↗
  32. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  33. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. First author DOI 10.1016/s1470-2045(21)00703-8↗
  34. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(22)00448-x↗
  35. Loss of FGFR4 promotes the malignant phenotype of PDAC. Co-author DOI 10.1038/s41388-022-02432-5↗
  36. Circulating tumour DNA: a challenging innovation to develop "precision onco-surgery" in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-022-01745-2↗
  37. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Last author DOI 10.1080/14728222.2022.2021397↗
  38. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  39. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  40. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  41. Detecting Lynch syndrome in pancreatic ductal adenocarcinoma FNA cytology based on cancer history and immunocytochemistry. First author DOI 10.1136/gutjnl-2021-326033↗
  42. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. Co-author DOI 10.1245/s10434-022-11417-3↗
  43. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  44. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  45. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. Co-author DOI 10.1093/bjs/znaa031↗
  46. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Co-author DOI 10.1136/gutjnl-2020-320726↗
  47. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Co-author DOI 10.1186/s13046-021-02153-9↗
  48. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Last author DOI 10.3390/cancers13133119↗
  49. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2020.04.006↗
  50. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗

Closest collaborators

The 25 strongest of 208 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aldo Scarpa · 36 shared papers, 2016–2026 · strength 5.03
  2. Roberto Salvia · 26 shared papers, 2019–2026 · strength 3.94
  3. Giuseppe Malleo · 23 shared papers, 2016–2026 · strength 3.47
  4. Rita Teresa Lawlor · 19 shared papers, 2018–2026 · strength 2.57
  5. Antonio Pea · 12 shared papers, 2018–2026 · strength 1.76
  6. Paola Mattiolo · 11 shared papers, 2020–2026 · strength 1.75
  7. Michèle Milella · 13 shared papers, 2019–2025 · strength 1.58
  8. Salvatore Paiella · 9 shared papers, 2020–2026 · strength 1.50
  9. Gabriella Lionetto · 8 shared papers, 2022–2026 · strength 1.50
  10. Claudio Bassi · 11 shared papers, 2019–2024 · strength 1.44
  11. Lodewijk A.A. Brosens · 10 shared papers, 2019–2025 · strength 1.27
  12. Iréne Esposito · 5 shared papers, 2021–2026 · strength 1.17
  13. Fabio Casciani · 6 shared papers, 2020–2026 · strength 1.13
  14. Matteo Fassan · 6 shared papers, 2016–2026 · strength 1.11
  15. Laura Maggino · 8 shared papers, 2020–2023 · strength 1.06
  16. Vincenzo Corbo · 7 shared papers, 2020–2025 · strength 0.97
  17. Giulio Belfiori · 5 shared papers, 2023–2026 · strength 0.95
  18. Massimo Falconi · 5 shared papers, 2023–2026 · strength 0.95
  19. Stefano Crippa · 5 shared papers, 2023–2026 · strength 0.95
  20. Andrea Mafficini · 7 shared papers, 2021–2025 · strength 0.92
  21. Alessandro Esposito · 5 shared papers, 2022–2026 · strength 0.89
  22. Giulia Gasparini · 4 shared papers, 2023–2026 · strength 0.75
  23. Giovanni Marchegiani · 6 shared papers, 2020–2024 · strength 0.71
  24. Massimo Donadelli · 3 shared papers, 2025–2026 · strength 0.68
  25. Carlotta Franzina · 3 shared papers, 2025–2026 · strength 0.66

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.